Accelerate AI-driven innovation and research and development synergy, join hands with the top international AI platform Schrdinger to catalyze the industrial upgrade of SIMCERE PHARMA (02096).

Drug research and development has always been known for its "high cost, long cycle, and high risk". According to statistics, in traditional R&D scenarios, it takes an average of 10-15 years and over $20 billion to bring an original new drug from discovery to market. How to break through this dilemma? SIMCERE PHARMA chooses to leverage globally renowned AI technology to restructure the drug development process, rapidly expand pipeline reserves, and accelerate the underlying transformation of its own innovative pharmaceutical R&D and commercialization logic. On July 10th, SIMCERE PHARMA (02096) announced that it had reached a global drug discovery and development cooperation agreement with the international AI leader Schrdinger. According to the agreement, the two parties will focus on unmet clinical needs, integrating SIMCERE PHARMA's R&D accumulation and clinical development capabilities in the fields of neuroscience, anti-tumor, autoimmunity, and anti-infection, as well as Schrdinger's globally leading physics-based and AI-driven drug design platform, to jointly promote the discovery and development of innovative drugs. By leveraging a leading international AI platform, accelerate the realization of high-value innovative assets For a pharmaceutical company committed to continuous commercialization and innovation realization, the growth of the company's investment value is closely related to its ability to convert research results. By relying on scarce AI technology platforms, efficiently driving the value realization of high-value innovative assets is a key reason why SIMCERE PHARMA has increased its investment in AI pharmaceuticals and chosen to form a strong alliance with Schrdinger. The cooperation between SIMCERE PHARMA and Schrdinger Company lays the foundation for enriching the company's self-developed innovative drug pipeline and accelerating the realization of high-value innovative assets. In recent years, SIMCERE PHARMA has undergone rapid transformation, becoming a domestic innovative pharmaceutical company with innovative capabilities and leading global clinical value, and a pipeline advancement speed at the forefront. Data shows that by 2025, SIMCERE PHARMA has already had 10 innovative drugs on the market, with over 60 innovative drugs in the pipeline. With strong innovation capabilities and nearly 9 billion R&D investment over the past 5 years driving growth, by 2025, innovative drug revenues accounted for 81.5% of SIMCERE PHARMA's total revenue. Continuous R&D investment not only drives the continuous realization of SIMCERE PHARMA's innovative pipeline but also makes "licensing out" a new growth engine for the company. By 2025, SIMCERE PHARMA had granted three early-stage research products in the anti-tumor field to international giants such as AbbVie and Ipsen; in January of this year, the company also licensed the overseas rights of its dual anti-cancer drug SIM0709 to Bristol-Myers Squibb, with a potential transaction value of 1.058 billion. The Company has now reached five external licensing agreements with a total potential transaction value exceeding $4.6 billion. This "R&D-licensing-reinvestment" model is becoming an important part of SIMCERE PHARMA's profit composition. Against this backdrop, joining hands with Schrdinger, SIMCERE PHARMA not only indicates that the company's multi-domain innovation research and development value has been strongly endorsed by the world's leading AI pharmaceutical giants, but also integrates AI deeply into the company's R&D system, continually improving the efficiency of investment in innovative research and development, and further unleashing SIMCERE PHARMA's advantages in R&D and commercialization in the fields of neuroscience, anti-tumor, autoimmunity, and anti-infection, continuously meeting the large unsatisfied treatment demands of the market while providing abundant momentum for the company's future growth. Innovative strength recognized by leading international AI platform In 2026, the global AI pharmaceutical industry officially transitioned from a "capital narrative" to a stage of large-scale implementation. In the process of industry development, Schrdinger, with its profound computational chemistry foundation and advanced machine learning algorithms, has won a unique and scarce advantage in the global AI pharmaceutical field. It is understood that Schrdinger has long focused on using AI computing platforms to accelerate drug development and material design, and through the deep integration of physics-based computational technology and AI, has built a powerful platform that serves both internal drug R&D and empowers global pharmaceutical companies and academic institutions. Based on analysis in the fields of physics and chemistry, this platform can accurately predict models, thereby discovering molecules of higher quality at lower costs and faster speeds. This computational platform can evaluate billions of compound molecules each week. In addition, the platform can iterate on compounds before synthesis and testing, comprehensively evaluating and optimizing them. Currently, Schrdinger has engaged in extensive cooperation with global leading pharmaceutical companies such as AstraZeneca and Bayer, and its AI pharmaceutical platform is being used by numerous biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It can be seen that Schrdinger Company has profound scientific cognition and rich development experience in the global AI pharmaceutical field. The reason why this company chose to cooperate with SIMCERE PHARMA is clearly due to the company's established R&D accumulation and clinical development capabilities in the fields of neuroscience, anti-tumor, autoimmunity, and anti-infection, and the strong endorsement of the company's innovative research and development strength by the international leading AI platform. For SIMCERE PHARMA, this cooperation with Schrdinger is not the company's first foray into AI pharmaceuticals. As early as 2020, SIMCERE PHARMA had collaborated with AI Medical Biology to conduct preliminary compound virtual screenings around targets in the fields of tumors, neuroscience, and autoimmunity, establishing a target-specific screening system using AI machine learning models. To further explore the potential of AI technology in the early stages of innovative drug development, SIMCERE PHARMA actively explored private deployment of AI and established various scenario applications, setting up an "AI+" department to accelerate AI applications. This collaboration with Schrdinger Company is clearly an important part of SIMCERE PHARMA's long-term strategic layout of "AI+". Collaborating with Schrdinger means that the company has gained a significant boost from its scarce AI platform technology in drug discovery and subsequent commercial development. This collaboration will be a deep integration and complementary of the technological efficiency of the AI platform and the strong innovative drug development capabilities. Conclusion Standing at the explosive inflection point of the large-scale implementation of AI pharmaceuticals, the collaboration between SIMCERE PHARMA and global AI technology giants has provided valuable experience for the industry. Its success lies not only in technical cooperation, but also in its synergistic research and development model of "leading AI platform + expert experience" the Schrdinger AI platform is responsible for screening and initial design, while SIMCERE PHARMA's scientists focus on key decision-making and optimization verification, and the combination unleashes innovative efficiency. Driven by multiple factors such as policy, technology, and capital, AI pharmaceuticals are transitioning from concepts to large-scale implementation. The deep collaboration between SIMCERE PHARMA and Schrdinger Company not only brings more efficient treatment solutions to patients but also provides important references for the industrial upgrade of China Meheco Group. It can be foreseen that as AI technology continues to evolve, the wave of intelligence in the innovative drug industry will sweep every corner and further accelerate the development process of innovative therapies, allowing global patients to enjoy the tremendous benefits brought by AI technology.